These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22891448)

  • 21. Prospects for personalized immunosuppression: pharmacologic tools--a review.
    Del Tacca M
    Transplant Proc; 2004 Apr; 36(3):687-9. PubMed ID: 15110631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring.
    Flexner CW
    Top HIV Med; 2003; 11(2):40-4. PubMed ID: 12717040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacologic monitoring and outcomes of cyclosporine.
    Pollard SG
    Transplant Proc; 2004 Mar; 36(2 Suppl):404S-407S. PubMed ID: 15041375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?
    MacPhee IA; Fredericks S; Holt DW
    Expert Opin Pharmacother; 2005 Dec; 6(15):2593-605. PubMed ID: 16316299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetics Biomarkers Predictive of Drug Pharmacodynamics as an Additional Tool to Therapeutic Drug Monitoring.
    Haufroid V; Picard N
    Ther Drug Monit; 2019 Apr; 41(2):121-130. PubMed ID: 30883506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation.
    Thervet E; Anglicheau D; Legendre C; Beaune P
    Ther Drug Monit; 2008 Apr; 30(2):143-50. PubMed ID: 18367973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical implementation of pharmacogenetics.
    García-González X; Cabaleiro T; Herrero MJ; McLeod H; López-Fernández LA
    Drug Metab Pers Ther; 2016 Mar; 31(1):9-16. PubMed ID: 26751902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacogenetics and immunosuppressor drugs: impact and clinical interest in transplantation].
    Marquet P; Djebli N; Picard N
    Ann Pharm Fr; 2007 Nov; 65(6):382-9. PubMed ID: 18079670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The dawn of precision medicine in HIV: state of the art of pharmacotherapy.
    Mu Y; Kodidela S; Wang Y; Kumar S; Cory TJ
    Expert Opin Pharmacother; 2018 Oct; 19(14):1581-1595. PubMed ID: 30234392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies.
    Eap CB; Jaquenoud Sirot E; Baumann P
    Ther Drug Monit; 2004 Apr; 26(2):152-5. PubMed ID: 15228156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs.
    Kurzawski M; Droździk M
    Pharmacogenomics; 2013 Jul; 14(9):1099-118. PubMed ID: 23837483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary?
    Mourad M; Wallemacq P; König J; de Frahan EH; Eddour DC; De Meyer M; Malaise J; Squifflet JP
    Clin Pharmacokinet; 2002; 41(5):319-27. PubMed ID: 12036390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacogenetics: a promising tool to personalize immunosuppressive therapy in renal transplantation].
    Caletti C; Granata S; Tomei P; Dalla Gassa A; Lupo A; Zaza G
    G Ital Nefrol; 2015; 32(3):. PubMed ID: 26093132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intra-cellular immunosuppressive drugs monitoring: A step forward towards better therapeutic efficacy after organ transplantation?
    Capron A; Haufroid V; Wallemacq P
    Pharmacol Res; 2016 Sep; 111():610-618. PubMed ID: 27468645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic drug monitoring of cancer chemotherapy.
    Alnaim L
    J Oncol Pharm Pract; 2007 Dec; 13(4):207-21. PubMed ID: 18045780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic drug monitoring of mycophenolate mofetil in transplantation.
    van Gelder T; Le Meur Y; Shaw LM; Oellerich M; DeNofrio D; Holt C; Holt DW; Kaplan B; Kuypers D; Meiser B; Toenshoff B; Mamelok RD
    Ther Drug Monit; 2006 Apr; 28(2):145-54. PubMed ID: 16628123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations.
    Zhang X; Lin G; Tan L; Li J
    Biomed Pharmacother; 2018 Jun; 102():107-114. PubMed ID: 29550633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations.
    del Mar Fernández De Gatta M; Santos-Buelga D; Domínguez-Gil A; García MJ
    Clin Pharmacokinet; 2002; 41(2):115-35. PubMed ID: 11888332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent development in application of high performance liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressants.
    Yang Z; Wang S
    J Immunol Methods; 2008 Jul; 336(2):98-103. PubMed ID: 18547583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature.
    Arns W; Cibrik DM; Walker RG; Mourad G; Budde K; Mueller EA; Vincenti F
    Transplantation; 2006 Oct; 82(8):1004-12. PubMed ID: 17060847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.